Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management

Stefan A. Koerber, Gerald Stach, Clemens Kratochwil, Matthias F. Haefner, Henrik Rathke, Klaus Herfarth, Klaus Kopka, Tim Holland-Letz, Peter L. Choyke, Uwe Haberkorn, Juergen Debus and Frederik L. Giesel
Journal of Nuclear Medicine January 2020, 61 (1) 46-50; DOI: https://doi.org/10.2967/jnumed.119.227637
Stefan A. Koerber
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
2National Center for Tumor Diseases, Heidelberg, Germany
3Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald Stach
4Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Kratochwil
4Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias F. Haefner
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
2National Center for Tumor Diseases, Heidelberg, Germany
3Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Rathke
4Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Herfarth
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
2National Center for Tumor Diseases, Heidelberg, Germany
3Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
6Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Kopka
7Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
8German Cancer Consortium, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Holland-Letz
9Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter L. Choyke
10Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
4Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juergen Debus
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
2National Center for Tumor Diseases, Heidelberg, Germany
3Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
6Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
8German Cancer Consortium, Heidelberg, Germany
11Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik L. Giesel
4Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
8German Cancer Consortium, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 1 46-50
DOI 
https://doi.org/10.2967/jnumed.119.227637
PubMed 
31302638

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 21, 2019
  • Accepted for publication May 13, 2019
  • Published online January 2, 2020.

Article Versions

  • previous version (July 13, 2019 - 08:11).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Stefan A. Koerber1–3,
  2. Gerald Stach4,
  3. Clemens Kratochwil4,5,
  4. Matthias F. Haefner1–3,
  5. Henrik Rathke4,
  6. Klaus Herfarth1–36,
  7. Klaus Kopka7,8,
  8. Tim Holland-Letz9,
  9. Peter L. Choyke10,
  10. Uwe Haberkorn4,5,
  11. Juergen Debus1–36,8,11 and
  12. Frederik L. Giesel4,5,8
  1. 1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
  2. 2National Center for Tumor Diseases, Heidelberg, Germany
  3. 3Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
  4. 4Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  5. 5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  6. 6Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
  7. 7Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
  8. 8German Cancer Consortium, Heidelberg, Germany
  9. 9Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany
  10. 10Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and
  11. 11Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
  1. For correspondence or reprints contact: Frederik L. Giesel, Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: frederik.giesel{at}med.uni-heidelberg.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 26 Citations
  • 30 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer
    Masoud Farshbaf, Ahmad Yari Khosroushahi, Solmaz Mojarad-Jabali, Amir Zarebkohan, Hadi Valizadeh, Paul R. Walker
    Journal of Controlled Release 2020 328
  • PSMA PET in Imaging Prostate Cancer
    Ioannis Tsechelidis, Alexis Vrachimis
    Frontiers in Oncology 2022 12
  • Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
    Melline G.M. Schilham, Patrik Zamecnik, Bastiaan M. Privé, Bas Israël, Mark Rijpkema, Tom Scheenen, Jelle O. Barentsz, James Nagarajah, Martin Gotthardt
    Journal of Nuclear Medicine 2021 62 9
  • Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
    Stefan A. Koerber, Katharina Sprute, Clemens Kratochwil, Erik Winter, Matthias F. Haefner, Sonja Katayama, Ingmar Schlampp, Klaus Herfarth, Klaus Kopka, Ali Afshar-Oromieh, Stefanie Zschaebitz, Tim Holland-Letz, Peter L. Choyke, Dirk Jaeger, Markus Hohenfellner, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 1
  • Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
    Jeremie Calais, Shaojun Zhu, Nader Hirmas, Matthias Eiber, Boris Hadaschik, Martin Stuschke, Ken Herrmann, Johannes Czernin, Amar U. Kishan, Nicholas G. Nickols, David Elashoff, Wolfgang P. Fendler
    BMC Cancer 2021 21 1
  • Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer
    Céline Derwael, Olivier Lavergne, Pierre Lovinfosse, Vlad Nechifor, Mallory Salvé, David Waltregny, Roland Hustinx, Nadia Withofs
    EJNMMI Research 2020 10 1
  • Automated segmentation of lesions and organs at risk on [68Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR
    Elmira Yazdani, Najme Karamzadeh-Ziarati, Seyyed Saeid Cheshmi, Mahdi Sadeghi, Parham Geramifar, Habibeh Vosoughi, Mahmood Kazemi Jahromi, Saeed Reza Kheradpisheh
    Cancer Imaging 2024 24 1
  • Artificial Intelligence Combined With Big Data to Predict Lymph Node Involvement in Prostate Cancer: A Population-Based Study
    Liwei Wei, Yongdi Huang, Zheng Chen, Hongyu Lei, Xiaoping Qin, Lihong Cui, Yumin Zhuo
    Frontiers in Oncology 2021 11
  • A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging
    Andrew F. Voter, Rudolf A. Werner, Hatice Savas, Andrei Gafita, Ashley E. Ross, Michael A. Gorin, Lilja B. Solnes, Martin G. Pomper, Steven P. Rowe, Sara Sheikhbahaei
    Seminars in Nuclear Medicine 2024 54 1
  • Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga‐PSMA‐PET/CT in prostate cancer patients candidate to definitive radiotherapy
    Cem Onal, Gokhan Ozyigit, Ezgi Oymak, Ozan Cem Guler, Pervin Hurmuz, Burak Tilki, Mehmet Reyhan, Murat Tuncel, Fadil Akyol
    The Prostate 2021 81 10

Article usage

Article usage: July 2019 to April 2025

AbstractFullPdf
Jul 2019479058
Aug 2019203028
Sep 201997016
Oct 2019115010
Nov 20196707
Dec 201983010
Jan 2020132429105
Feb 2020356945
Mar 2020184442
Apr 2020122838
May 2020115470
Jun 2020103458
Jul 2020971958
Aug 2020743895
Sep 202012532120
Oct 20206928110
Nov 20206623143
Dec 2020564996
Jan 20214319167
Feb 20213016169
Mar 20213324159
Apr 20212022542
May 20211718042
Jun 20211718955
Jul 20211620052
Aug 20211319853
Sep 20212820047
Oct 20213722162
Nov 20211917481
Dec 20211716240
Jan 20223016147
Feb 20221619959
Mar 20221410657
Apr 20221718746
May 2022718843
Jun 2022108744
Jul 20221414229
Aug 2022918252
Sep 2022619430
Oct 20221216538
Nov 20221617334
Dec 2022722519
Jan 20232229135
Feb 20231727941
Mar 2023935553
Apr 2023525657
May 2023923342
Jun 20231021423
Jul 2023919631
Aug 20231021229
Sep 2023620728
Oct 20231123144
Nov 2023220120
Dec 2023420624
Jan 2024523424
Feb 2024523228
Mar 2024722949
Apr 2024942838
May 2024429525
Jun 2024819325
Jul 2024422732
Aug 20241428431
Sep 20241126048
Oct 2024733730
Nov 2024930330
Dec 2024224232
Jan 2025426228
Feb 20251133519
Mar 20251426032
Apr 20251030128
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (1)
Journal of Nuclear Medicine
Vol. 61, Issue 1
January 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management
Stefan A. Koerber, Gerald Stach, Clemens Kratochwil, Matthias F. Haefner, Henrik Rathke, Klaus Herfarth, Klaus Kopka, Tim Holland-Letz, Peter L. Choyke, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel
Journal of Nuclear Medicine Jan 2020, 61 (1) 46-50; DOI: 10.2967/jnumed.119.227637

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management
Stefan A. Koerber, Gerald Stach, Clemens Kratochwil, Matthias F. Haefner, Henrik Rathke, Klaus Herfarth, Klaus Kopka, Tim Holland-Letz, Peter L. Choyke, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel
Journal of Nuclear Medicine Jan 2020, 61 (1) 46-50; DOI: 10.2967/jnumed.119.227637
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • KEY POINTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
  • The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Clinical

Similar Articles

Keywords

  • prostate cancer
  • PSMA
  • PET/CT
  • Roach formula
  • Virchow
SNMMI

© 2025 SNMMI

Powered by HighWire